



VICTORIA UNIVERSITY
MELBOURNE AUSTRALIA

Focus on extracellular vesicles: exosomes and their role in protein trafficking and biomarker potential in Alzheimer's and Parkinson's disease

This is the Published version of the following publication

Vella, Laura, Hill, Andrew F and Cheng, Lesley (2016) Focus on extracellular vesicles: exosomes and their role in protein trafficking and biomarker potential in Alzheimer's and Parkinson's disease. *International Journal of Molecular Sciences*, 17 (2). ISSN 1661-6596

The publisher's official version can be found at
<https://www.mdpi.com/1422-0067/17/2/173>

Note that access to this version may require subscription.

Downloaded from VU Research Repository <https://vuir.vu.edu.au/45590/>



Review

Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's Disease

Laura J. Vella ¹, Andrew F. Hill ^{2,*} and Lesley Cheng ²

¹ The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3010, Australia; ljvella@unimelb.edu.au

² Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3083, Australia; l.cheng@latrobe.edu.au

* Correspondence: andrew.hill@latrobe.edu.au; Tel.: +61-394-791-224

Academic Editor: Ritva Tikkanen

Received: 12 August 2015; Accepted: 21 October 2015; Published: 6 February 2016

Abstract: Growing evidence indicates that small extracellular vesicles, called exosomes, are prominent mediators of neurodegenerative diseases such as prion, Alzheimer's and Parkinson's disease. Exosomes contain neurodegenerative disease associated proteins such as the prion protein, β -amyloid and α -synuclein. Only demonstrated so far *in vivo* with prion disease, exosomes are hypothesised to also facilitate the spread of β -amyloid and α -synuclein from their cells of origin to the extracellular environment. In the current review, we will discuss the role of exosomes in Alzheimer's and Parkinson's disease including their possible contribution to disease propagation and pathology and highlight their utility as a diagnostic in neurodegenerative disease.

Keywords: exosomes; extracellular vesicles; neurodegeneration; protein trafficking; protein misfolding; Alzheimer's disease; Parkinson's disease; biomarkers

1. Introduction

Neurodegenerative diseases including Alzheimer's, Parkinson's and prion disease have distinct clinical manifestations and molecular pathology however they share common features such as aggregation of disease specific proteins. These include β -amyloid ($A\beta$) in Alzheimer's disease (AD), α -synuclein (α -syn) in Parkinson's disease (PD) and the prion protein (PrP) in prion disease. Further commonalities exist, namely those observed at the anatomical level revealing spread of $A\beta$ and α -syn is in a non-random, topographically predictable manner in the brain [1,2]. Cell-to-cell contact and passive spread were initially deemed responsible; however, more recently small extracellular vesicles, called exosomes, were proposed to play a role [3,4]. A comprehensive introduction into extracellular vesicles, including exosomes, is provided in this focus edition by Kalra *et al.* [5].

Exosomes are released into the extracellular environment by most cell types and play an important role in inter-cellular communication. In the central nervous system (CNS), exosomes can mediate neuronal and glia communication, promote neuronal repair and growth and contribute to the progression of glioblastoma and neurodegenerative disease [6–9] (for a review see [10]). Once released from the donor cell, exosomes act as discrete vesicles travelling to distant and proximal recipient cells to alter cell function and phenotype. In the case of prion disease, exosomes alter recipient cell function by transmitting infectivity and initiating a cascade of events that further spreads and propagates the disease (for a review see [3]).

The idea that exosomes may be involved in the spreading of pathology in other neurodegenerative diseases such as AD and PD has recently gained considerable attention with $A\beta$ and α -syn postulated

to spread and propagate via a similar mechanism to PrP [11,12]. Here, we review the recent literature regarding the possible roles of exosomes in AD and PD and discuss their potential in biomarker discovery.

2. Alzheimer's Disease

Alzheimer's disease is characterized by the presence of insoluble plaques and tangles composed of A β and hyper-phosphorylated tau (p-tau), respectively. The accumulation of A β has been shown to interfere with synaptic plasticity which is required for neuronal signaling and implicated in pro-apoptotic signaling leading to neuronal loss. The pathological process is slow with pre-clinical AD likely to extend for more than two decades [13]. During this period, it is speculated that there is a gradual reduction of A β clearance in the brain and an increase in A β accumulation which causes the pathological hallmarks observed in late AD.

2.1. Association of APP and Its Metabolites with Exosomes

The A β isoform 1-42 (A β 42) has been shown to play a key role in the pathology of AD due to its ability to form both intracellular and extracellular fibrils and aggregates. A β is produced from the processing of the amyloid precursor protein (APP) which is synthesized in the endoplasmic reticulum (ER) and then transported through the Golgi apparatus to the trans-Golgi-network (TGN). From the TGN, APP is transported to the plasma membrane driven by TGN secretory vesicles where it is then cleaved by β - and γ -secretases [14] to produce A β . A β can also be generated in the ER and Golgi within the presence of the β - and γ -secretases causing the intracellular accumulation of A β [15]. γ -secretase is able to cleave APP at various positions producing a number of isoforms of monomeric A β ranging from 39 to 43 residues in length. The liberated A β peptide, in particular, A β 42 accumulates extracellularly and overtime assembles into oligomers and protofibrils leading to amyloid plaque formation (reviewed in [16]). APP at the plasma membrane can be re-internalised back through the endocytic and recycling organelles and also via the endosomal/lysosomal degradation pathway where A β can be generated where γ -secretase is located [17,18]. Furthermore, APP can be directly trafficked from the Golgi to lysosomes where it is cleaved and A β can rapidly aggregate in lysosomes due to the low pH conditions in lysosomes [19]. As A β 42 has a high propensity to aggregate, it may be likely that this isoform is protected from degradation in the lysosome and the aggregates could eventually be released upon stress-induced cell death [19]. In AD, the lysosomal and proteasomal systems have been found to be dysfunctional in certain areas of the AD brain when compared to healthy controls [20]. It is likely that the endosomal/lysosomal system sits at a crossroad between A β production and degradation thus endosomal/lysosomal dysfunction may contribute to the early pathological changes seen in AD.

An endosomal organelle that fuses with lysosomes is the multi-vesicular body (MVB), also known as the late endosome compartment, which arises from the maturation of the early endosome. It is this point where contents of the MVBs can be sent for lysosomal degradation, recycled back to the trans-Golgi network or plasma membrane. Several studies have demonstrated that A β peptides can be packaged into intraluminal vesicles (ILVs) within the MVBs and upon fusion of the MVB with the plasma membrane the ILVs are released into extracellular environment as exosomes [21]. The role of exosomes in AD was initially explored using APP overexpressing cell lines whereby the appearance of C-terminal fragments (CTFs) of APP and A β were observed in exosomes [22,23]. It is plausible that exosomes containing A β are released to clear and regulate rising intracellular A β levels. A summary of the literature demonstrating A β and its association with exosomes can be viewed in Table 1.

Table 1. Studies pertaining to amyloid- β , exosomes and Alzheimer's disease.

Exosome Source	Findings	Transfer?	Ref.
<i>In Vitro Source</i>			
SKNSH-SY5Y cells (differentiated) expressing WT APP	<ul style="list-style-type: none"> APP, CTFs-APP and the amyloid intracellular domain in exosomes. 	×	[22]
CHO cells expressing WT APP	<ul style="list-style-type: none"> CTFs-APP, Aβ and several key members of the secretase family of proteases (BACE, PS1, PS2 and ADAM10) found in exosomes. 	×	[23]
N2a cells expressing human A β PP Swedish mutation	<ul style="list-style-type: none"> Insulin-Degrading Enzyme found in exosomes is proteolytically active and assists in the degradation of endogenous Aβ. 	×	[24]
N2a and primary cultured hippocampal cells of <i>Prnp</i> ^{+/+} and <i>Prnp</i> ^{-/-} mice	<ul style="list-style-type: none"> Immobilization of Aβ oligomers occurs through binding of PrP^C at the surface of exosomes. 	×	[25]
N2a and BV-2 cells	<ul style="list-style-type: none"> Exosomes promote conformational changes in Aβ to form nontoxic amyloid fibrils. Exosomes are internalized into microglia to aid in Aβ degradation. 	✓	[26]
Mouse primary astrocytes and neurons	<ul style="list-style-type: none"> Astrocyte derived exosomes contain ceramide and PAR4 which were taken up by astrocytes to promote exosome-mediated astrocyte cell death. 	✓	[27]
Mouse primary astrocytes and neurons	<ul style="list-style-type: none"> Inhibition of sphingomyelinase by GW4869 reduced levels of exosomes secretion and consequently Aβ plaque formation. Exosomes containing Aβ42 injected into brains of an AD mice model (5XFAD) instigate aggregation of Aβ. 	×	[28]

Table 1. Cont.

Exosome Source	Findings	Transfer?	Ref.
<i>In Vitro Source</i>			
BE(2)-M17D cells expressing WT tau (inducible)	<ul style="list-style-type: none"> Exosomes contained AD associated N-terminal phosphor-tau epitopes which was also validated in CSF samples collected from AD patients. 	×	[29]
Dendritic cells transfected with Lamp2b fused to the neuron-specific rabies viral glycoprotein peptide	<ul style="list-style-type: none"> Exosomes loaded with siRNA targeted to BACE1 were delivered into recipient cells in culture and <i>in vivo</i> resulting in the knockdown of BACE1 and a decrease in the total β-amyloid 1–42 levels. 	✓	[30]
Brains of transgenic mice overexpressing human APP	<ul style="list-style-type: none"> APP, CTFs-APP, $A\beta$ and several key members of the secretase family of proteases (BACE and ADAM10) were found contained in exosomes. 	×	[31]
CSF collected from Cynomolgus monkeys and APP transgenic mice in addition to primary neuronal and N2a cells	<ul style="list-style-type: none"> CSF exosomes contained $A\beta$. Glycosphingolipid enriched neuronal derived exosomes were able to capture $A\beta$ as a mode of $A\beta$ clearance. 	×	[32,33]
Mouse serum of 5XFAD mice	<ul style="list-style-type: none"> Increase of exosomes in serum from ceramide treated mice. Ceramide treated mice were found to display increased Thioflavin S positive plaques. 	×	[34]
Human serum and plasma	<ul style="list-style-type: none"> Detection of elevated total tau, P-T181-tau, P-S396-tau and $A\beta$42 by ELISA in AD patients compared to controls. 	×	[35]

Recent reports suggest exosomes, which are usually isolated from extracellular fluid, can be extracted from brain tissue [28,31,36–38]. Perez-Gonzalez *et al.* first described the method, using it to isolate vesicles from the brains of Tg2576 mice (transgenic mice overexpressing human APP with the K670N/M671L Swedish double mutation) [31]. They observed increased levels of full length APP, CTFs–APP fragments, and A β in “exosomes” from brains of Tg2576 mice compared to wild type mice [31]. Using a similar isolation method, Dinkins *et al.*, reported that exosome reduction *in vivo* is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer’s disease [28]. Although interesting findings, the minimal experimental requirements for the definition of exosomes [39] were not met in these studies, making it difficult to draw conclusions from the data presented [28].

There is evidence to suggest that exosomes have a protective role in neurodegeneration (reviewed in [40]). Exosomes can also deliver beneficial factors such as proteolytically active plasma membrane derived insulin degrading enzyme to assist in degrading extracellular A β [24]. Other data has suggested that proteins found on the surface of exosomes such as the cellular prion protein (PrP^C), a cell membrane-bound glycoprotein, can sequester A β induced synaptic dysfunction in the brain suggesting that exosomes have a protective role in the brain of AD patients [25]. The addition of neuron-derived exosomes with A β 42 was found to facilitate a rapid conformational change of A β into nontoxic amyloid fibrils which were internalized by microglia and delivered to lysosomes, aiding A β degradation [26]. This supports the observation that microglia were demonstrated to internalize secreted exosomes for degradation as seen by the accumulation of labelled exosomes found within Lamp-1 positive late endosomal or lysosomal compartments in cultured microglia cells [41].

A growing number of studies have shown that dysfunction of autophagy plays a critical role in A β metabolism and the pathogenesis of AD [42,43]. Autophagosomes contain A β cleaving enzymes in addition to A β [44] and more recently has been shown to mediate A β secretion [43]. Autophagosomes containing A β can fuse with MVBs to form amphisomes and potentially release their ILVs in the form of exosomes upon fusion with the plasma membrane [45] leading to the extracellular release of A β . The induction of autophagy by rapamycin *in vivo* has been shown to lower intracellular A β levels leading to improved cognition [46]. Conversely, autophagy-deficient APP transgenic mice through the knockout of autophagy-related gene 7 (Atg7) displayed an increase in intracellular A β accumulation which lead to neurodegeneration and cognitive impairment [43]. In the same study, extracellular A β was found to be reduced possibly indicating that autophagy deficiency impairs secretion of A β to the extracellular environment.

Ultimately, as AD progresses into its advance stages the accumulation of toxic A β aggregates eventually overwhelms any potential mechanism of clearance. The role of exosome remains controversial [40]; however, further research will provide insight into whether exosomes are driving the accumulation of A β pathology or providing a method of releasing neurotoxic A β , likely identifying potential therapeutics to balance A β metabolism.

2.2. Association of Tau with Exosomes

In addition to amyloid plaques, aggregation of intracellular hyperphosphorylated microtubule-associated tau protein leading to neurofibrillary tangles is a common pathological feature of AD. The spread of tau occurs after A β plaque deposition which is firstly observed in the hippocampus and the temporal cortex. Tau pathology spreads to various areas of the brain responsible for specific sensors or motor function and consequently patients are observed to experience loss of cognitive function (reviewed in [11]). The mechanism behind the secretion and spread of tau has achieved less attention compared to A β . This is most likely due to the first hypothesis that tau was released following neuronal death or via an exocytic process [47]. *In vitro* studies using tau-overexpressing lines have demonstrated tau secretion can be mediated by exosomes and passive secretion [29,48,49]. More recently, using healthy untransfected neuronal cultures including neuroblastoma Neuro2a (N2a) cells and human cortical induced pluripotent stem cells (iPSCs),

less than 1% of extracellular tau was found in exosomes while the majority of tau was found to be free-floating consisting of truncated c-terminal fragments of tau. Interestingly, isolating neutrally derived blood exosomes from a total exosome preparation using immunocapture using antibodies targeting neural cell adhesion molecule (NCAM), increased levels of p-tau, P-S396-tau and P-T181-tau were detected in AD patients compared to healthy controls [35]. Further biochemical studies are required to determine whether hyperphosphorylated tau associated with AD is found in exosomes within *in vitro* and *in vivo* models.

3. Parkinson's Disease

PD is a neurodegenerative disease which can be characterised by bradykinesia, resting tremor and postural instability. In PD, the signature histopathological lesions are known as Lewy bodies (LBs). Whereas the mechanisms underlying the clinical and pathological features of PD remain to be defined, the protein α -syn clearly plays a central role in the disease process being the main component of LBs.

Association of α -Synuclein with Exosomes

Following the identification of α -syn in biological fluids including CSF [50] and blood [51], it became clear that α -syn was not exclusively an intracellular protein. Although the mechanism of α -syn release has not been fully elucidated, a role for the mitochondrial, autophagy and endosomal pathways is apparent. Both mutation and overexpression of α -syn result in aberrant processing and degradation in these pathways leading to release of both exosome associated and free α -syn into the extracellular environment [52–54]. The first indication that α -syn could be externalised via exosomes was provided by Emmanouilidou *et al.*, showing that exosomes derived from the conditioned media of the SH-SY5Y cell line contained α -syn [52]. This finding has since been confirmed by others in neuronal cell culture models, primary dermal fibroblasts [53–59] and *in vivo* [60,61]. In addition to being found in association with exosomes, α -syn has been identified in conditioned media and CSF not exosome associated [53,57,60,62]. It has been suggested that unlike the prion protein, extracellular α -syn is predominantly free with exosomes representing a small pool of the total extracellular α -syn [58,62–65]. Further studies are required to ascertain if this is indeed the case *in vivo*.

Increasing evidence suggests that exosome formation and release maybe modulated by the autophagy-lysosome pathway (ALP), whereby autophagy induction promotes exosome release, while conditions that stimulate autophagy can inhibit exosome release [45,66]. Impairments in the ALP are hallmarks of both sporadic and genetic forms of PD [67] suggesting that exosome release may be enhanced in PD. Indeed, pharmacological modulators of ALP, such as bafilomycin, inhibit fusion of the autophagosome to the lysosome, consequently enhancing the release of α -syn in association with exosomes [53,54,59]. Bafilomycin treatment of H4 cells transfected with α -syn reduced intracellular α -syn aggregation but increased secretion of smaller oligomers by exosomes and RAB11A-associated pathways whereas high-aggregated α -syn was secreted by membrane shedding [59]. The mitochondrial complex I inhibitor, rotenone, is an environmental toxin, known to induce PD [68]. Rotenone impairs mitochondrial function but is also suggested to impair autophagic flux and lysosomal functions [69]. When treated with rotenone, enteric neurons release a greater number of exosomes containing α -syn [58]. Whilst bafilomycin and rotenone promote exosome release, the autophagy enhancer rapamycin decreased α -syn oligomer signal in exosomes, suggesting that enhanced lysosomal activity decreases exosomes release and providing further evidence of deregulated exosome release in PD.

A number of genes linked to PD have roles in autophagic and endocytic pathways including, LRRK2, VPS35 and PARK9 with evidence slowly coming to light linking these genes to exosome biogenesis and release. LRRK2 protein is implicated in protein sorting, trafficking and autophagy and is released in association with exosomes [70,71], VPS35 is involved in endosomal trafficking [72] and PARK9 protein is a P-type transport ATPase found in MVBs [55,73] and shown to regulate exosome biogenesis [55,56]. Elevated PARK9 expression increased α -syn externalization in exosomes

from SH-SY5Y and H4 cells and mouse primary cortical neurons [55,56]. Interestingly, PARK9 overexpression reduced intracellular α -syn levels in SH-SY5Ys and increased α -syn externalization in exosomes [55]. By contrast, PD patient fibroblasts with loss of PARK9 function have a decreased number of intraluminal vesicles in MVBs and diminished release of exosomes into culture media [56]. Whether PARK9-mediated externalization benefits the exporting cell by decreasing intracellular levels of α -syn but consequently confers α -syn toxicity to surrounding cells is unknown [55]. Kong *et al.* proposed that the increased export of exosome-associated α -syn may explain why surviving neurons of the substantia nigra pars compacta in sporadic PD patients were observed to over-express PARK9 [55,74].

Together, these studies suggest that α -syn is released into the extracellular environment when cellular pathways fail. The importance, however, of an exosome *versus* exosome independent pathway to α -syn spread and propagation is still unclear and an area of intense study. A summary of the literature demonstrating α -syn and its association with exosomes can be viewed in Table 2.

Table 2. Studies pertaining to α -synuclein, exosomes and Parkinson's disease.

Exosome Source	Findings	Transfer?	Ref.
<i>In Vitro Source</i>			
SH-SY5Y o/e WT α -syn	<ul style="list-style-type: none"> α-syn is constitutively secreted in exosomes and release of exosomal α-syn is calcium dependent. 	×	[52]
	<ul style="list-style-type: none"> Lysosomal dysfunction increases release of α-syn in exosomes and α-syn transmission to recipient cells. 	✓	[54]
SH-SY5Y cells (differentiated) expressing WT α -syn (inducible)	<ul style="list-style-type: none"> Only a small portion of secreted α-syn is in exosomes. Extracellular, not exosomal α-syn, alters recipient cell function. 	×	[57]
SH-SY5Y o/e WT or A53T α -syn	<ul style="list-style-type: none"> α-syn in neuronal cell media and CSF is abundant in the neat supernatant, not exosome. 	×	[62]
Primary neurons and H4 cells o/e WT α -syn	<ul style="list-style-type: none"> Autophagy regulates α-syn secretion. α-syn oligomers are located inside and outside exosomes and are more prone to internalization than exosome-free α-syn oligomers and induce greater toxicity. 	✓	[53]
PC12 cells o/e α -syn A30P-/+ p25 α	<ul style="list-style-type: none"> A small fraction (3% of total secreted α-syn) of α-syn monomer is associated with exosome. 	×	[63]
N2a cells WT and o/e α -syn	<ul style="list-style-type: none"> Exosomes catalyse aggregation of exogenous α-syn. 	×	[75]

Table 2. Cont.

Exosome Source	Findings	Transfer?	Ref.
<i>In Vitro Source</i>			
SH-SY5Y or HEK293 o/e WT α -syn with or without PARK9 expression	<ul style="list-style-type: none"> Elevated PARK9 expression reduces intracellular α-syn levels and increases α-syn externalization in exosomes. PARK9 regulates exosome biogenesis. 	×	[55]
mouse primary neurons (o/e or KD of PARK9) and patient fibroblasts	<ul style="list-style-type: none"> PARK9 regulates exosome biogenesis. The amount of α-syn in exosomes correlates with PARK9 expression. 	×	[56]
H4 cells o/e low or high aggregating α -syn	<ul style="list-style-type: none"> Low-aggregated α-syn is released by exosomes and RAB11A-associated pathways whereas high-aggregated α-syn is secreted via membrane shedding. 	×	[59]
Enteric primary neurons	<ul style="list-style-type: none"> Rotenone increases release of α-syn containing exosomes. 	×	[58]
Mouse and human plasma	<ul style="list-style-type: none"> α-syn in plasma L1CAM-containing exosomes is higher in PD compared to healthy controls. 	×	[60]
Patient urine and CSF	<ul style="list-style-type: none"> LRRK2 detected urine and CSF derived exosomes. 	×	[70]
Patient sera	<ul style="list-style-type: none"> 23 exosome-associated proteins differentially abundant in PD patient sera exosomes. Did not detect an enrichment of α-syn in PD patient sera derived exosomes. 	×	[76]
Patient urine	<ul style="list-style-type: none"> LRRK2 and DJ-1 detected in urinary exosomes. Increased DJ-1 in male PD patient urinary exosomes. 	×	[71]
Human CSF N2a and Oli-neu cells	<ul style="list-style-type: none"> α-syn is in human CSF exosomes and located inside exosomes, not outside. Sumoylation regulates exosomal release of α-syn. 	×	[61]

4. Use of Exosomes in Biomarker Discovery for Alzheimer's and Parkinson's Disease

Exosomes can be isolated from extracellular fluids including cerebrospinal fluid (CSF) [77,78], blood [79] and urine [80]. As exosomes represent an enriched source of biomolecules, including proteins and nucleic acids, they are hypothesized to provide a peripheral non-invasive biomarker for neurodegenerative diseases that would be more reliable than neat CSF, blood or urine [79].

Many groups have analyzed CSF levels of A β 42, total tau, p-tau, α -syn as biomarkers for neurodegenerative disease [35,81–86]. Variations in CSF biomarker measurements have been observed across laboratories. Studies have shown a significant decrease in CSF A β 42 levels [84,86] or an increase in both p-tau and A β 42 levels [35] in AD patients. Others have shown an increase in p-tau in AD patients but no significant correlation with CSF A β 42 levels in AD patients compared to healthy patients or non-AD dementia disorders [81]. Several studies have explored the potential use of α -syn as a PD diagnostic biomarker in CSF, but the results are inconsistent with some studies showing lower α -syn in the CSF of PD patients whereas other studies show no significant change [82,83].

Exosomes extracted from CSF were enriched in proteins derived from the brain such as microglia markers (CD11b and CD45), neuron specific markers (ENO2) and vesicle associated membrane protein 2 (VAMP2) [87]. Other proteins such as prion protein (PRNP), neurogenic locus notch homolog protein 3 (NOTCH3), apolipoprotein E (APOE) associated with neurodegenerative diseases were also enriched in CSF exosomes [87]. A significant increase of total tau and p-tau was detected in exosomal CSF samples collected from postmortem AD patients compared to controls [29]. However, the increase of total tau and p-tau was not detected in the same samples when using whole CSF owing to the observation that there was an enrichment of p-tau in the exosomal samples relative to whole CSF [29]. APP has also been detected in CSF exosomes [88] and in some cases found enriched in the supernatant rather than in the exosome fraction of CSF [87]. To our knowledge, α -syn has been found in association with CSF exosomes [64]; however, the diagnostic potential is yet to be explored.

LRRK2 and DJ-1, proteins implicated in PD, have been identified in urinary and CSF exosomes. Expression of LRRK2 in urinary exosomes was variable in clinical populations, making it difficult to assess possible LRRK2 changes between PD cases and controls [70]. The authors suggest that future studies with more samples may address some aspects of power, but it seems unlikely that the LRRK2 measurement in urine alone would provide a valuable diagnostic tool [70]. DJ-1 in urinary exosomes has been proposed as a biomarker for PD in males, although a detailed study with a larger sample size is required to validate preliminary studies [71]. Proteomic analysis of PD patient sera derived exosomes performed on grouped samples of patients with genetic and sporadic forms of PD and healthy subjects identified 23 exosome-associated proteins that were differentially abundant in PD, including the regulator of exosome biogenesis syntenin 1 [76]. These protein changes were detected despite similar exosome numbers across groups suggesting that they may reflect exosome sub populations with distinct functions or selective packaging. Based on the findings of this study, it would be worth investigating the biomarker potential of the identified proteins using a larger clinical PD cohort. There are several reports of cell-free plasma biomarkers for classifying AD patients from healthy controls [89–91]. Although these studies show high accuracy for predicting AD, the concern for using blood based biomarkers is the relevance to brain disease. Recently, the Goetzl laboratory undertook a different approach by using immunochemical methods to harvest and enrich for brain derived exosomes in blood using NCAM and L1 cell adhesion molecule (L1CAM) [35,92,93]. In particular, they were able to specifically analyze levels of A β and p-tau levels from exosomes possibly derived from the brain thus removing noise generated from a general pool of exosomes found in the bloodstream. Furthermore, 12%–17% of exosomes within the total plasma exosomal population expressed NCAM and L1CAM [35]; however, it is not conclusive whether the immunocaptured exosomes are bona-fide exosomes due to the lack of characterization published in their studies. NCAM and L1CAM are not specifically unique to the brain as they are also expressed throughout the renal system [94,95]. Using a similar approach, α -syn was detected in human plasma derived exosomes (L1-CAM antibody captured), with patient (267 PD patients) plasma exosomes containing elevated levels of α -syn relative

to healthy controls (215 aged matched) [60]. Total plasma α -syn levels remained unchanged [60] and no change was found in patient sera derived exosomes [76], suggesting that L1-CAM antibodies may capture a distinct, possibly CNS derived, exosome population [60]. These immunochemical capture methods provide a novel approach to improve specificity of disease biomarkers.

The nervous system is a rich source of miRNA [96], which may reflect the onset and stages of neurodegenerative disease [97]. Although miRNA can be found in CSF, they are more abundant in blood and have greater stability. Profiling of circulating miRNA associated with AD has been performed by various groups [91,98,99] and others have shown some or no correlation with CSF biomarkers [100,101]. While most of these studies utilize free circulating miRNA, exosomes provide a protective environment for the extracellular transfer of genetic material and have been shown to be enriched with miRNA species [79,102]. Using human serum collected from AD patients and healthy controls, a panel of 16 miRNAs was found to be differentially expressed in exosomes of AD patients which correlated with other methods of diagnosis such as brain-imaging, neuropsychometric testing and APOE ϵ 4 genotyping [103]. This demonstrates the feasibility of using exosomal miRNA as a complementary tool with other biomarkers to act as a pre-screening tool for both AD and PD. The profile of exosomal miRNA in PD patient blood has not yet been determined; however, it should be explored given reports of deregulated miRNA in PD patient blood and brain tissue [104–108].

In future studies, it would be interesting to determine whether brain derived exosomes contain the miRNA species detected in peripheral exosomes and whether exosomal miRNA are able to disrupt gene expression to further promote neurodegeneration.

5. Conclusions

5.1. A Role for Exosomes in Protein Propagation in Alzheimer's and Parkinson's Disease?

A number of studies have indicated that A β and α -syn exhibit a prion-like self-propagation characteristic causing these toxic proteins to further aggregate and form assemblies of small oligomers to large plaques or inclusions. The deposited proteins act as a template to instigate further progression of the disease which then spread throughout the brain. The putative spread of these neurotoxic lesions has been proposed to be mediated by exosomes. An increasing number of studies has demonstrated that the propagation of the prion protein that occurs in prion diseases, such as Creutzfeldt-Jakob disease, is via an exosomal pathway [109,110]. The infectious prion protein replicates by recruiting and converting the cellular form of the prion protein (PrP^C) to the abnormal protein isoform (PrP^{Sc}). The infectious pathogen can then be incorporated into exosomes as a mode of cell-to-cell contact to spread infection through tissues of the lymphoreticular system before invading the central nervous system as reviewed in [3], raising the question—does A β and α -syn propagation occur via a similar mechanism?

A β seeds have been shown to initiate A β accumulation and spread in the brain through studies using APP transgenic mice and performing intracerebral injections of A β -rich brain material from patients with AD or from aged APP transgenic mice [111]. A β lesions were observed to spread throughout the neocortex and hippocampal region followed by the thalamus and septal nuclei within 12 months of the intracerebral injection of A β rich extract [112]. Evidence of internalization has been described by studies investigating cell-to-cell transfer of A β [113,114]. Differentiated SH-SY5Y cells were able to transfer tagged A β peptides which were internalised in co-culture experiments [114]. The internalised A β co-localized with lysosomes; however, the exact mechanism of transfer was not investigated [114]. The phenomenon suggests that A β can be transferred cell-to-cell and potentially spread the pathology throughout the brain. Furthermore, astrocytes treated with amyloid peptides were found to trigger release of pro-apoptotic exosomes containing ceramide and PAR4 (prostate apoptosis response 4) [27]. These exosomes were taken up by astrocytes to further promote apoptosis, leading to exosome-mediated astrocyte cell death and potentially contributing to neurodegeneration [27].

Other studies have demonstrated that microvesicles (MVs) can play a harmful role by contributing to the accumulation of extracellular toxic A β in the brain. MVs are larger plasma membrane-derived vesicles of approximately 100–1000 nm which are secreted through the outward budding of the cell surface. Together with exosomes, MVs have also been shown to play an important role in cell-to-cell communication. Joshi *et al.* demonstrated that microglia-derived MVs provided an endogenous source of lipids to promote the formation of neurotoxic A β 42 [115]. This supports the observation that lipids are able to activate fibrillisation of monomeric A β [116]. To further fuel the generation of neurotoxic A β , activated microglia found surrounding amyloid plaques were found to internalise A β 42 leading to aggregation of A β 42 in association with MVs as seen by confocal microscopy [115]. In the same study, exosomes secreted from microglia were also found to contain A β 42, significantly less, however, compared to MVs.

To demonstrate the seeding hypothesis in tauopathies, tau fibrils were transduced into tau-overexpressing cells which promoted the misfolding and fibrillisation of intracellular tau resembling neurofibrillary tangles [117]. The uptake of tau seeds was found to occur spontaneously through absorptive endocytosis whereby only a small quantity of tau fibrils was required to instigate the development of intracellular filamentous tau. Furthermore, the spread of tau through interconnected regions of the brain has also been demonstrated to induce tauopathy in tau-transgenic mice [118,119].

Fetal mesencephalic grafts transplanted into the striatum of patients with PD develop α -syn positive and ubiquitin positive Lewy bodies more than a decade after transplantation, suggesting that α -syn oligomers and pathology can transfer from host-to-graft [120,121] and that α -syn has “prion-like” activity. Indeed, exosomes are capable of transferring α -syn to recipient cells *in vitro* [52–54] with α -syn oligomers associated with exosomes more toxic to recipient cells compared to non-exosome associated α -syn oligomers [53]. Although non-exosome associated α -syn can be taken up by cells, exosome α -syn oligomers are more prone to internalization by recipient cells [53] with transmission to recipient cells relative to the amount of α -syn released from the donor cells [54]. If disrupted by sonication prior to incubation with recipient cells, exosomal α -syn transfer is prevented, indicating that intact exosomes are required for efficient transfer and subsequent neurotoxicity [53,54].

There is increasing evidence that interactions with lipid bilayers play a role in α -syn aggregation and the pathogenesis of PD [75,122,123]. Using Thioflavin T fluorescence to monitor aggregation kinetics, Grey *et al.* recently found that exosomes catalyze the aggregation of α -syn in a similar manner to low concentrations of preformed α -syn fibrils [75]. Aggregation of exogenous α -syn was accelerated by exosomes irrespective of whether they were derived from control cells or cells over-expressing α -syn. Lipid vesicles prepared from extracted exosome lipids accelerated aggregation, suggesting that the lipids in exosomes were sufficient for the catalytic effect to arise [75].

Identification of the mechanisms of cell-to-cell transmission of pathology-associated proteins would provide a molecular pathway that could be targeted by novel therapies with the aim of disrupting or delaying spread and the subsequent progression of disease. The importance of an exosome *versus* exosome independent pathway to A β and α -syn spread and propagation is still unclear and remains an area of intense study.

5.2. The Use of Exosomes as Therapeutics

The discovery that double-stranded RNA (RNA interference; RNAi) could silence genes by degrading mRNA in a sequence-specific manner led to investigations into the use of RNAi for therapeutic purposes [124,125]. As siRNA can be rapidly degraded, there has been substantial interest in using exosomes for the delivery of siRNA *in vivo*. Cooper *et al.* developed modified exosomes that specifically target the brain by expressing a brain-targeting peptide (rabies virus glycoprotein peptide; RVG) [126] and loaded them with α -syn siRNA. To evaluate whether this approach could decrease α -syn aggregates in the brain, mice expressing the human phosphorylation-mimic S129D α -syn were injected with RVG-exosomes loaded with siRNA α -syn. This resulted in decreased α -syn mRNA and

protein levels throughout the brain seven days after injection and reductions in intraneuronal protein aggregates, including in dopaminergic neurons of the substantia nigra [126]. A similar approach using RVG-exosomes was also used to deliver siRNA targeted to knockdown BACE1, a therapeutic target for AD [30]. More recently, intracerebral administration of exosomes enriched with glycosphingolipids was able to clear extracellular A β resulting in a decreased deposition of A β in the brain of APP transgenic mice [32,33]. However, recent work from Dinkins *et al.* administered subcutaneous ceramide injections to 5XFAD mice to increase circulating exosomes and aid exosome-mediated clearance of A β [34]. Although amyloid levels did not significantly change, ceramide-treated 5XFAD mice displayed an increase in cortical plaque number [34]. Further work needs to be carried out to determine whether increasing or decreasing exosome secretion is beneficial in human AD.

An exosomal-based delivery system for the antioxidant, catalase, has been tested *in vitro* and *in vivo* for models of PD [127]. Catalase loaded exosomes (generated *ex vivo*) were readily taken up by neuronal cells *in vitro* and some exosomes were detected in PD mouse brains following intranasal administration. The catalase loaded exosomes provided neuroprotective effects in an *in vivo* model of PD by decreasing neuroinflammation [127]. These novel approaches pave the way to clinical trials aimed at exosome delivery of siRNA or next generation drug delivery via exosomes to delay a range of neurodegenerative diseases including Alzheimer's and Parkinson's disease.

In the last decade, there has been an increasing trend of research into exosomes which has expanded into neurodegenerative diseases. The body of evidence demonstrates that exosomes play an important part in communication in the brain. Although so far only confirmed in prion disease, the consensus in the field is that exosomes function as Trojan horses facilitating the accumulation and spread of neurodegenerative disease associated protein in the brain with *in vivo* data to support this hypothesis in AD and PD forthcoming. Upon understanding the physical nature of exosomes, it may be possible to manipulate their contents to deliver therapeutic factors to delay the onset of neurodegeneration.

For further information on the basic properties of extracellular vesicles, their involvement in malignant diseases, their role in cell-to-cell communication, as drug delivery vehicles, and as stem cell-derived therapeutics, the reader is referred to the various reviews of this focus edition [5,128–131].

Acknowledgments: Andrew F. Hill is supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship.

Author Contributions: Laura J. Vella, Andrew F. Hill, and Lesley Cheng conceived and wrote the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Braak, H.; del Tredici, K.; Rub, U.; de vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol. Aging* **2003**, *24*, 197–211. [[CrossRef](#)]
2. Braak, H.; Braak, E. Neuropathological staging of alzheimer-related changes. *Acta Neuropathol.* **1991**, *82*, 239–259. [[CrossRef](#)] [[PubMed](#)]
3. Coleman, B.M.; Hill, A.F. Extracellular vesicles—Their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases. *Semin. Cell Dev. Biol.* **2015**, *40*, 89–96. [[CrossRef](#)] [[PubMed](#)]
4. Russo, I.; Bubacco, L.; Greggio, E. Exosomes-associated neurodegeneration and progression of Parkinson's disease. *Am. J. Neurodegener. Dis.* **2012**, *1*, 217–225. [[PubMed](#)]
5. Kalra, H.; Drummen, G.P.C.; Mathivanan, S. Focus on extracellular vesicles: An introduction to the next small big thing. *Int. J. Mol. Sci.* **2016**, *17*. [[CrossRef](#)] [[PubMed](#)]
6. Frohlich, D.; Kuo, W.P.; Fruhbeis, C.; Sun, J.J.; Zehendner, C.M.; Luhmann, H.J.; Pinto, S.; Toedling, J.; Trotter, J.; Kramer-Albers, E.M. Multifaceted effects of oligodendroglial exosomes on neurons: Impact on neuronal firing rate, signal transduction and gene regulation. *Philos. Trans. R. Soc. Lond B Biol. Sci.* **2014**, *369*. [[CrossRef](#)] [[PubMed](#)]
7. Fruhbeis, C.; Frohlich, D.; Kuo, W.P.; Kramer-Albers, E.M. Extracellular vesicles as mediators of neuron-glia communication. *Front. Cell. Neurosci.* **2013**, *7*. [[CrossRef](#)] [[PubMed](#)]

8. Skog, J.; Wurdinger, T.; van Rijn, S.; Meijer, D.H.; Gainche, L.; Sena-Esteves, M.; Curry, W.T., Jr.; Carter, B.S.; Krichevsky, A.M.; Breakefield, X.O. Glioblastoma microvesicles transport rna and proteins that promote tumour growth and provide diagnostic biomarkers. *Nat. Cell Biol.* **2008**, *10*, 1470–1476. [[CrossRef](#)] [[PubMed](#)]
9. Bronisz, A.; Wang, Y.; Nowicki, M.O.; Peruzzi, P.; Ansari, K.I.; Ogawa, D.; Balaj, L.; de Rienzo, G.; Mineo, M.; Nakano, I.; *et al.* Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. *Cancer Res.* **2014**, *74*, 738–750. [[CrossRef](#)] [[PubMed](#)]
10. Rajendran, L.; Bali, J.; Barr, M.M.; Court, F.A.; Kramer-Albers, E.M.; Picou, F.; Raposo, G.; van der vos, K.E.; van Niel, G.; Wang, J.; *et al.* Emerging roles of extracellular vesicles in the nervous system. *J. Neurosci.* **2014**, *34*, 15482–15489. [[CrossRef](#)] [[PubMed](#)]
11. Vingtdeux, V.; Sergeant, N.; Buee, L. Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer's disease. *Front. Physiol.* **2012**, *3*. [[CrossRef](#)] [[PubMed](#)]
12. Bellingham, S.A.; Guo, B.B.; Coleman, B.M.; Hill, A.F. Exosomes: Vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? *Front. Physiol.* **2012**, *3*. [[CrossRef](#)] [[PubMed](#)]
13. Villemagne, V.L.; Burnham, S.; Bourgeat, P.; Brown, B.; Ellis, K.A.; Salvado, O.; Szoek, C.; Macaulay, S.L.; Martins, R.; Maruff, P.; *et al.* Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. *Lancet Neurol.* **2013**, *12*, 357–367. [[CrossRef](#)]
14. Cataldo, A.M.; Petanceska, S.; Terio, N.B.; Peterhoff, C.M.; Durham, R.; Mercken, M.; Mehta, P.D.; Buxbaum, J.; Haroutunian, V.; Nixon, R.A. A β localization in abnormal endosomes: Association with earliest A β elevations in ad and down syndrome. *Neurobiol. Aging* **2004**, *25*, 1263–1272. [[CrossRef](#)] [[PubMed](#)]
15. Hartmann, T.; Bieger, S.C.; Bruhl, B.; Tienari, P.J.; Ida, N.; Allsop, D.; Roberts, G.W.; Masters, C.L.; Dotti, C.G.; Unsicker, K.; *et al.* Distinct sites of intracellular production for Alzheimer's disease A β 40/42 amyloid peptides. *Nat. Med.* **1997**, *3*, 1016–1020. [[CrossRef](#)] [[PubMed](#)]
16. Jucker, M.; Walker, L.C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. *Nature* **2013**, *501*, 45–51. [[CrossRef](#)] [[PubMed](#)]
17. Caporaso, G.L.; Takei, K.; Gandy, S.E.; Matteoli, M.; Mundig, O.; Greengard, P.; de Camilli, P. Morphologic and biochemical analysis of the intracellular trafficking of the Alzheimer β /A4 amyloid precursor protein. *J. Neurosci.* **1994**, *14*, 3122–3138. [[PubMed](#)]
18. Tam, J.H.; Seah, C.; Pasternak, S.H. The Amyloid Precursor Protein is rapidly transported from the Golgi apparatus to the lysosome and where it is processed into β -amyloid. *Mol. Brain* **2014**, *7*. [[CrossRef](#)] [[PubMed](#)]
19. Hu, X.; Crick, S.L.; Bu, G.; Frieden, C.; Pappu, R.V.; Lee, J.M. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid- β peptide. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 20324–20329. [[CrossRef](#)] [[PubMed](#)]
20. Keller, J.N.; Hanni, K.B.; Markesbery, W.R. Impaired proteasome function in Alzheimer's disease. *J. Neurochem.* **2000**, *75*, 436–439. [[CrossRef](#)] [[PubMed](#)]
21. Rajendran, L.; Honsho, M.; Zahn, T.R.; Keller, P.; Geiger, K.D.; Verkade, P.; Simons, K. Alzheimer's disease β -amyloid peptides are released in association with exosomes. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 11172–11177. [[CrossRef](#)] [[PubMed](#)]
22. Vingtdeux, V.; Hamdane, M.; Loyens, A.; Gele, P.; Drobeck, H.; Begard, S.; Galas, M.C.; Delacourte, A.; Beauvillain, J.C.; Buee, L.; *et al.* Alkalinizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies. *J. Biol. Chem.* **2007**, *282*, 18197–18205. [[CrossRef](#)] [[PubMed](#)]
23. Sharples, R.A.; Vella, L.J.; Nisbet, R.M.; Naylor, R.; Perez, K.; Barnham, K.J.; Masters, C.L.; Hill, A.F. Inhibition of γ -secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. *FASEB J.* **2008**, *22*, 1469–1478. [[CrossRef](#)] [[PubMed](#)]
24. Bulloj, A.; Leal, M.C.; Xu, H.; Castano, E.M.; Morelli, L. Insulin-degrading enzyme sorting in exosomes: A secretory pathway for a key brain amyloid- β degrading protease. *J. Alzheimer's Dis.* **2010**, *19*, 79–95.
25. An, K.; Klyubin, I.; Kim, Y.; Jung, J.H.; Mably, A.J.; O'Dowd, S.T.; Lynch, T.; Kanmert, D.; Lemere, C.A.; Finan, G.M.; *et al.* Exosomes neutralize synaptic-plasticity-disrupting activity of A β assemblies *in vivo*. *Mol. Brain* **2013**, *6*, 47. [[CrossRef](#)] [[PubMed](#)]
26. Yuyama, K.; Sun, H.; Mitsutake, S.; Igarashi, Y. Sphingolipid-modulated exosome secretion promotes clearance of amyloid- β by microglia. *J. Biol. Chem.* **2012**, *287*, 10977–10989. [[CrossRef](#)] [[PubMed](#)]

27. Wang, G.; Dinkins, M.; He, Q.; Zhu, G.; Poirier, C.; Campbell, A.; Mayer-Proschel, M.; Bieberich, E. Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4): Potential mechanism of apoptosis induction in Alzheimer disease (AD). *J. Biol. Chem.* **2012**, *287*, 21384–21395. [[CrossRef](#)] [[PubMed](#)]
28. Dinkins, M.B.; Dasgupta, S.; Wang, G.; Zhu, G.; Bieberich, E. Exosome reduction *in vivo* is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease. *Neurobiol. Aging* **2014**, *35*, 1792–1800. [[CrossRef](#)] [[PubMed](#)]
29. Saman, S.; Kim, W.; Raya, M.; Visnick, Y.; Miro, S.; Saman, S.; Jackson, B.; McKee, A.C.; Alvarez, V.E.; Lee, N.C.; *et al.* Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. *J. Biol. Chem.* **2012**, *287*, 3842–3849. [[CrossRef](#)] [[PubMed](#)]
30. Alvarez-Erviti, L.; Seow, Y.; Yin, H.; Betts, C.; Lakkh, S.; Wood, M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat. Biotechnol.* **2011**, *29*, 341–345. [[CrossRef](#)] [[PubMed](#)]
31. Perez-Gonzalez, R.; Gauthier, S.A.; Kumar, A.; Levy, E. The exosome secretory pathway transports amyloid precursor protein carboxyl-terminal fragments from the cell into the brain extracellular space. *J. Biol. Chem.* **2012**, *287*, 43108–43115. [[CrossRef](#)] [[PubMed](#)]
32. Yuyama, K.; Sun, H.; Sakai, S.; Mitsutake, S.; Okada, M.; Tahara, H.; Furukawa, J.; Fujitani, N.; Shinohara, Y.; Igarashi, Y. Decreased amyloid- β pathologies by intracerebral loading of glycosphingolipid-enriched exosomes in Alzheimer model mice. *J. Biol. Chem.* **2014**, *289*, 24488–24498. [[CrossRef](#)] [[PubMed](#)]
33. Yuyama, K.; Sun, H.; Usuki, S.; Sakai, S.; Hanamatsu, H.; Mioka, T.; Kimura, N.; Okada, M.; Tahara, H.; Furukawa, J.; *et al.* A potential function for neuronal exosomes: Sequestering intracerebral amyloid- β peptide. *FEBS Lett.* **2015**, *589*, 84–88. [[CrossRef](#)] [[PubMed](#)]
34. Dinkins, M.B.; Dasgupta, S.; Wang, G.; Zhu, G.; He, Q.; Kong, J.N.; Bieberich, E. The 5XFAD mouse model of Alzheimer's disease exhibits an age-dependent increase in anti-ceramide IGG and exogenous administration of ceramide further increases anti-ceramide titers and amyloid plaque burden. *J. Alzheimer's Dis.* **2015**, *46*, 55–61. [[CrossRef](#)] [[PubMed](#)]
35. Fiandaca, M.S.; Kapogiannis, D.; Mapstone, M.; Boxer, A.; Eitan, E.; Schwartz, J.B.; Abner, E.L.; Petersen, R.C.; Federoff, H.J.; Miller, B.L.; *et al.* Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. *Alzheimer's Dement.* **2014**, *11*, 600–607. [[CrossRef](#)] [[PubMed](#)]
36. Banigan, M.G.; Kao, P.F.; Kozubek, J.A.; Winslow, A.R.; Medina, J.; Costa, J.; Schmitt, A.; Schneider, A.; Cabral, H.; Cagsal-Getkin, O.; *et al.* Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. *PLoS ONE* **2013**, *8*, e48814. [[CrossRef](#)] [[PubMed](#)]
37. Pituch, K.C.; Moyano, A.L.; Lopez-Rosas, A.; Marottoli, F.M.; Li, G.; Hu, C.; van Breemen, R.; Mansson, J.E.; Givogri, M.I. Dysfunction of platelet-derived growth factor receptor α (PDGFR α) represses the production of oligodendrocytes from arylsulfatase A-deficient multipotential neural precursor cells. *J. Biol. Chem.* **2015**, *290*, 7040–7053. [[CrossRef](#)] [[PubMed](#)]
38. Yelamanchili, S.V.; Lamberty, B.G.; Rennard, D.A.; Morse, B.M.; Hochfelder, C.G.; Meays, B.M.; Levy, E.; Fox, H.S. miR-21 in extracellular vesicles leads to neurotoxicity via TLR7 signaling in *siv* neurological disease. *PLoS Pathog.* **2015**, *11*, e1005032. [[CrossRef](#)] [[PubMed](#)]
39. Lotvall, J.; Hill, A.F.; Hochberg, F.; Buzas, E.I.; di Vizio, D.; Gardiner, C.; Gho, Y.S.; Kurochkin, I.V.; Mathivanan, S.; Quesenberry, P.; *et al.* Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the international society for extracellular vesicles. *J. Extracell. Vesicles* **2014**, *3*. [[CrossRef](#)] [[PubMed](#)]
40. Joshi, P.; Benussi, L.; Furlan, R.; Ghidoni, R.; Verderio, C. Extracellular vesicles in Alzheimer's disease: Friends or foes? Focus on A β -vesicle interaction. *Int. J. Mol. Sci.* **2015**, *16*, 4800–4813. [[CrossRef](#)] [[PubMed](#)]
41. Fitzner, D.; Schnaars, M.; van Rossum, D.; Krishnamoorthy, G.; Dibaj, P.; Bakhti, M.; Regen, T.; Hanisch, U.K.; Simons, M. Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis. *J. Cell Sci.* **2011**, *124*, 447–458. [[CrossRef](#)] [[PubMed](#)]
42. Nixon, R.A.; Wegiel, J.; Kumar, A.; Yu, W.H.; Peterhoff, C.; Cataldo, A.; Cuervo, A.M. Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. *J. Neuropathol. Exp. Neurol.* **2005**, *64*, 113–122. [[CrossRef](#)] [[PubMed](#)]

43. Nilsson, P.; Loganathan, K.; Sekiguchi, M.; Matsuba, Y.; Hui, K.; Tsubuki, S.; Tanaka, M.; Iwata, N.; Saito, T.; Saido, T.C. A β secretion and plaque formation depend on autophagy. *Cell Rep.* **2013**, *5*, 61–69. [[CrossRef](#)] [[PubMed](#)]
44. Yu, W.H.; Cuervo, A.M.; Kumar, A.; Peterhoff, C.M.; Schmidt, S.D.; Lee, J.H.; Mohan, P.S.; Mercken, M.; Farmery, M.R.; Tjernberg, L.O.; *et al.* Macroautophagy—A novel β -amyloid peptide-generating pathway activated in Alzheimer's disease. *J. Cell Biol.* **2005**, *171*, 87–98. [[CrossRef](#)] [[PubMed](#)]
45. Fader, C.M.; Sanchez, D.; Furlan, M.; Colombo, M.I. Induction of autophagy promotes fusion of multivesicular bodies with autophagic vacuoles in k562 cells. *Traffic (Cph. Den.)* **2008**, *9*, 230–250. [[CrossRef](#)] [[PubMed](#)]
46. Caccamo, A.; Majumder, S.; Richardson, A.; Strong, R.; Oddo, S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid- β , and tau: Effects on cognitive impairments. *J. Biol. Chem.* **2010**, *285*, 13107–13120. [[CrossRef](#)] [[PubMed](#)]
47. Frost, B.; Jacks, R.L.; Diamond, M.I. Propagation of tau misfolding from the outside to the inside of a cell. *J. Biol. Chem.* **2009**, *284*, 12845–12852. [[CrossRef](#)] [[PubMed](#)]
48. Chai, X.; Dage, J.L.; Citron, M. Constitutive secretion of tau protein by an unconventional mechanism. *Neurobiol. Dis.* **2012**, *48*, 356–366. [[CrossRef](#)] [[PubMed](#)]
49. Simon, D.; Garcia-Garcia, E.; Royo, F.; Falcon-Perez, J.M.; Avila, J. Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. *FEBS Lett.* **2012**, *586*, 47–54. [[CrossRef](#)] [[PubMed](#)]
50. Borghi, R.; Marchese, R.; Negro, A.; Marinelli, L.; Forloni, G.; Zaccheo, D.; Abbruzzese, G.; Tabaton, M. Full length α -synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. *Neurosci. Lett.* **2000**, *287*, 65–67. [[CrossRef](#)]
51. El-Agnaf, O.M.; Salem, S.A.; Paleologou, K.E.; Cooper, L.J.; Fullwood, N.J.; Gibson, M.J.; Curran, M.D.; Court, J.A.; Mann, D.M.; Ikeda, S.; *et al.* α -synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. *FASEB J.* **2003**, *17*, 1945–1947. [[CrossRef](#)] [[PubMed](#)]
52. Emmanouilidou, E.; Melachroinou, K.; Roumeliotis, T.; Garbis, S.D.; Ntzouni, M.; Margaritis, L.H.; Stefanis, L.; Vekrellis, K. Cell-produced α -synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. *J. Neurosci.* **2010**, *30*, 6838–6851. [[CrossRef](#)] [[PubMed](#)]
53. Danzer, K.M.; Kranich, L.R.; Ruf, W.P.; Cagsal-Getkin, O.; Winslow, A.R.; Zhu, L.; Vanderburg, C.R.; McLean, P.J. Exosomal cell-to-cell transmission of α synuclein oligomers. *Mol. Neurodegener.* **2012**, *7*. [[CrossRef](#)] [[PubMed](#)]
54. Alvarez-Erviti, L.; Seow, Y.; Schapira, A.H.; Gardiner, C.; Sargent, I.L.; Wood, M.J.; Cooper, J.M. Lysosomal dysfunction increases exosome-mediated α -synuclein release and transmission. *Neurobiol. Dis.* **2011**, *42*, 360–367. [[CrossRef](#)] [[PubMed](#)]
55. Kong, S.M.; Chan, B.K.; Park, J.S.; Hill, K.J.; Aitken, J.B.; Cottle, L.; Farghaian, H.; Cole, A.R.; Lay, P.A.; Sue, C.M.; *et al.* Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α -synuclein externalization via exosomes. *Hum. Mol. Genet.* **2014**, *23*, 2816–2833. [[CrossRef](#)] [[PubMed](#)]
56. Tsunemi, T.; Hamada, K.; Krainc, D. ATP13A2/PARK9 regulates secretion of exosomes and α -synuclein. *J. Neurosci.* **2014**, *34*, 15281–15287. [[CrossRef](#)] [[PubMed](#)]
57. Melachroinou, K.; Xilouri, M.; Emmanouilidou, E.; Masgrau, R.; Papazafiri, P.; Stefanis, L.; Vekrellis, K. Deregulation of calcium homeostasis mediates secreted α -synuclein-induced neurotoxicity. *Neurobiol. Aging* **2013**, *34*, 2853–2865. [[CrossRef](#)] [[PubMed](#)]
58. Pan-Montojo, F.; Schwarz, M.; Winkler, C.; Arnhold, M.; O'Sullivan, G.A.; Pal, A.; Said, J.; Marsico, G.; Verbavatz, J.M.; Rodrigo-Angulo, M.; *et al.* Environmental toxins trigger PD-like progression via increased α -synuclein release from enteric neurons in mice. *Sci. Rep.* **2012**, *2*, 898. [[CrossRef](#)] [[PubMed](#)]
59. Poehler, A.M.; Xiang, W.; Spitzer, P.; May, V.; Meixner, H.; Rockenstein, E.; Chutna, O.; Outeiro, T.; Winkler, J.; Masliah, E.; *et al.* Autophagy modulates SNCA/ α -synuclein release, thereby generating a hostile microenvironment. *Autophagy* **2014**, *10*, 2171–2192. [[CrossRef](#)] [[PubMed](#)]
60. Shi, M.; Liu, C.; Cook, T.J.; Bullock, K.M.; Zhao, Y.; Ginghina, C.; Li, Y.; Aro, P.; Dator, R.; He, C.; *et al.* Plasma exosomal α -synuclein is likely CNS-derived and increased in Parkinson's disease. *Acta Neuropathol.* **2014**, *128*, 639–650. [[CrossRef](#)] [[PubMed](#)]

61. Kunadt, M.; Eckermann, K.; Stuendl, A.; Gong, J.; Russo, B.; Strauss, K.; Rai, S.; Kugler, S.; Falomir Lockhart, L.; Schwalbe, M.; *et al.* Extracellular vesicle sorting of α -synuclein is regulated by sumoylation. *Acta Neuropathol.* **2015**, *129*, 695–713. [[CrossRef](#)] [[PubMed](#)]
62. Hasegawa, T.; Konno, M.; Baba, T.; Sugeno, N.; Kikuchi, A.; Kobayashi, M.; Miura, E.; Tanaka, N.; Tamai, K.; Furukawa, K.; *et al.* The AAA-ATPASE VPS4 regulates extracellular secretion and lysosomal targeting of α -synuclein. *PLoS ONE* **2011**, *6*, e29460. [[CrossRef](#)] [[PubMed](#)]
63. Ejlerskov, P.; Rasmussen, I.; Nielsen, T.T.; Bergstrom, A.L.; Tohyama, Y.; Jensen, P.H.; Vilhardt, F. Tubulin polymerization-promoting protein (TPPP/p25 α) promotes unconventional secretion of α -synuclein through exophagy by impairing autophagosome-lysosome fusion. *J. Biol. Chem.* **2013**, *288*, 17313–17335. [[CrossRef](#)] [[PubMed](#)]
64. Grathwohl, S.A.; Steiner, J.A.; Britschgi, M.; Brundin, P. Mind the gut: Secretion of α -synuclein by enteric neurons. *J. Neurochem.* **2013**, *125*, 487–490. [[CrossRef](#)] [[PubMed](#)]
65. Paillusson, S.; Clairembault, T.; Biraud, M.; Neunlist, M.; Derkinderen, P. Activity-dependent secretion of α -synuclein by enteric neurons. *J. Neurochem.* **2013**, *125*, 512–517. [[CrossRef](#)] [[PubMed](#)]
66. Baixauli, F.; Lopez-Otin, C.; Mittelbrunn, M. Exosomes and autophagy: Coordinated mechanisms for the maintenance of cellular fitness. *Front. Immunol.* **2014**, *5*. [[CrossRef](#)] [[PubMed](#)]
67. Damme, M.; Suntio, T.; Saftig, P.; Eskelinen, E.L. Autophagy in neuronal cells: General principles and physiological and pathological functions. *Acta Neuropathol.* **2014**, *129*, 337–362. [[CrossRef](#)] [[PubMed](#)]
68. Betarbet, R.; Sherer, T.B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A.V.; Greenamyre, J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. *Nat. Neurosci.* **2000**, *3*, 1301–1306. [[PubMed](#)]
69. Wu, F.; Xu, H.D.; Guan, J.J.; Hou, Y.S.; Gu, J.H.; Zhen, X.C.; Qin, Z.H. Rotenone impairs autophagic flux and lysosomal functions in Parkinson's disease. *Neuroscience* **2015**, *284*, 900–911. [[CrossRef](#)] [[PubMed](#)]
70. Fraser, K.B.; Moehle, M.S.; Daher, J.P.; Webber, P.J.; Williams, J.Y.; Stewart, C.A.; Yacoubian, T.A.; Cowell, R.M.; Dokland, T.; Ye, T.; *et al.* LRRK2 secretion in exosomes is regulated by 14-3-3. *Hum. Mol. Genet.* **2013**, *22*, 4988–5000. [[CrossRef](#)] [[PubMed](#)]
71. Ho, D.H.; Yi, S.; Seo, H.; Son, I.; Seol, W. Increased DJ-1 in urine exosome of Korean males with Parkinson's disease. *Biomed. Res. Int.* **2014**, *2014*, 704678. [[CrossRef](#)] [[PubMed](#)]
72. Follett, J.; Norwood, S.J.; Hamilton, N.A.; Mohan, M.; Kovtun, O.; Tay, S.; Zhe, Y.; Wood, S.A.; Mellick, G.D.; Silburn, P.A.; *et al.* The VPS35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer. *Traffic* **2014**, *15*, 230–244. [[CrossRef](#)] [[PubMed](#)]
73. Van Veen, S.; Sorensen, D.M.; Holemans, T.; Holen, H.W.; Palmgren, M.G.; Vangheluwe, P. Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson's disease and other neurological disorders. *Front. Mol. Neurosci.* **2014**, *7*. [[CrossRef](#)] [[PubMed](#)]
74. Ramirez, A.; Heimbach, A.; Grundemann, J.; Stiller, B.; Hampshire, D.; Cid, L.P.; Goebel, I.; Mubaidin, A.F.; Wriekat, A.L.; Roeper, J.; *et al.* Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 p-type atpase. *Nat. Genet.* **2006**, *38*, 1184–1191. [[CrossRef](#)] [[PubMed](#)]
75. Grey, M.; Dunning, C.J.; Gaspar, R.; Grey, C.; Brundin, P.; Sparr, E.; Linse, S. Acceleration of α -synuclein aggregation by exosomes. *J. Biol. Chem.* **2015**, *290*, 2969–2982. [[CrossRef](#)] [[PubMed](#)]
76. Tomlinson, P.R.; Zheng, Y.; Fischer, R.; Heidasch, R.; Gardiner, C.; Evetts, S.; Hu, M.; Wade-Martins, R.; Turner, M.R.; Morris, J.; *et al.* Identification of distinct circulating exosomes in Parkinson's disease. *Ann. Clin. Transl. Neurol.* **2015**, *2*, 353–361. [[CrossRef](#)] [[PubMed](#)]
77. Vella, L.J.; Greenwood, D.L.; Cappai, R.; Scheerlinck, J.P.; Hill, A.F. Enrichment of prion protein in exosomes derived from ovine cerebral spinal fluid. *Vet. Immunol. Immunopathol.* **2008**, *124*, 385–393. [[CrossRef](#)] [[PubMed](#)]
78. Street, J.M.; Barran, P.E.; Mackay, C.L.; Weidt, S.; Balmforth, C.; Walsh, T.S.; Chalmers, R.T.; Webb, D.J.; Dear, J.W. Identification and proteomic profiling of exosomes in human cerebrospinal fluid. *J. Transl. Med.* **2012**, *10*. [[CrossRef](#)] [[PubMed](#)]
79. Cheng, L.; Sharples, R.A.; Scicluna, B.J.; Hill, A.F. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. *J. Extracell. Vesicles* **2014**, *3*. [[CrossRef](#)] [[PubMed](#)]
80. Cheng, L.; Sun, X.; Scicluna, B.J.; Coleman, B.M.; Hill, A.F. Characterization and deep sequencing analysis of exosomal and non-exosomal mirna in human urine. *Kidney Int.* **2013**, *86*, 433–444. [[CrossRef](#)] [[PubMed](#)]

81. Lin, Y.T.; Cheng, J.T.; Yao, Y.C.; Juo, Lo, Y.K.; Lin, C.H.; Ger, L.P.; Lu, P.J. Increased total tau but not amyloid- β (42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease. *J. Alzheimer's Dis.* **2009**, *18*, 907–918.
82. Parnetti, L.; Castrioto, A.; Chiasserini, D.; Persichetti, E.; Tambasco, N.; El-Agnaf, O.; Calabresi, P. Cerebrospinal fluid biomarkers in Parkinson disease. *Nat. Rev. Neurol.* **2013**, *9*, 131–140. [[CrossRef](#)] [[PubMed](#)]
83. Zhou, B.; Wen, M.; Yu, W.F.; Zhang, C.L.; Jiao, L. The diagnostic and differential diagnosis utility of cerebrospinal fluid α -synuclein levels in Parkinson's disease: A meta-analysis. *Parkinson's Dis.* **2015**, *2015*, 567386.
84. Riemenschneider, M.; Schmolke, M.; Lautenschlager, N.; Guder, W.G.; Vanderstichele, H.; Vanmechelen, E.; Kurz, A. Cerebrospinal β -amyloid_(1–42) in early Alzheimer's disease: Association with apolipoprotein e genotype and cognitive decline. *Neurosci. Lett.* **2000**, *284*, 85–88. [[CrossRef](#)]
85. Andreasen, N.; Hesse, C.; Davidsson, P.; Minthon, L.; Wallin, A.; Winblad, B.; Vanderstichele, H.; Vanmechelen, E.; Blennow, K. Cerebrospinal fluid β -amyloid_(1–42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease. *Arch. Neurol.* **1999**, *56*, 673–680. [[CrossRef](#)] [[PubMed](#)]
86. Seeburger, J.L.; Holder, D.J.; Combrinck, M.; Joachim, C.; Laterza, O.; Tanen, M.; Dallob, A.; Chappell, D.; Snyder, K.; Flynn, M.; *et al.* Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the optima cohort. *J. Alzheimer's Dis.* **2014**, *44*, 525–539.
87. Chiasserini, D.; van Weering, J.R.; Piersma, S.R.; Pham, T.V.; Malekzadeh, A.; Teunissen, C.E.; de Wit, H.; Jimenez, C.R. Proteomic analysis of cerebrospinal fluid extracellular vesicles: A comprehensive dataset. *J. Proteom.* **2014**, *106*, 191–204. [[CrossRef](#)] [[PubMed](#)]
88. Lopez-Font, I.; Cuchillo-Ibanez, I.; Sogorb-Esteve, A.; Garcia-Ayllon, M.S.; Saez-Valero, J. Transmembrane amyloid-related proteins in CSF as potential biomarkers for Alzheimer's disease. *Front. Neurol.* **2015**, *6*, 125. [[CrossRef](#)] [[PubMed](#)]
89. Hye, A.; Lynham, S.; Thambisetty, M.; Causevic, M.; Campbell, J.; Byers, H.L.; Hooper, C.; Rijdsdijk, F.; Tabrizi, S.J.; Banner, S.; *et al.* Proteome-based plasma biomarkers for Alzheimer's disease. *Brain* **2006**, *129*, 3042–3050. [[CrossRef](#)] [[PubMed](#)]
90. Mapstone, M.; Cheema, A.K.; Fiandaca, M.S. Plasma phospholipids identify antecedent memory impairment in older adults. *Nat. Med.* **2014**, *20*, 415–418. [[CrossRef](#)] [[PubMed](#)]
91. Kumar, P.; Dezso, Z.; MacKenzie, C.; Oestreicher, J.; Agoulnik, S.; Byrne, M.; Bernier, F.; Yanagimachi, M.; Aoshima, K.; Oda, Y. Circulating miRNA biomarkers for Alzheimer's disease. *PLoS ONE* **2013**, *8*, e69807. [[CrossRef](#)]
92. Kapogiannis, D.; Boxer, A.; Schwartz, J.B.; Abner, E.L.; Biragyn, A.; Masharani, U.; Frassetto, L.; Petersen, R.C.; Miller, B.L.; Goetzl, E.J. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease. *FASEB J.* **2014**, *29*, 589–596. [[CrossRef](#)] [[PubMed](#)]
93. Goetzl, E.J.; Boxer, A.; Schwartz, J.B.; Abner, E.L.; Petersen, R.C.; Miller, B.L.; Kapogiannis, D. Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. *Neurology* **2015**, *85*, 40–47. [[CrossRef](#)] [[PubMed](#)]
94. Allory, Y.; Audard, V.; Fontanges, P.; Ronco, P.; Debiec, H. The I1 cell adhesion molecule is a potential biomarker of human distal nephron injury in acute tubular necrosis. *Kidney Int.* **2008**, *73*, 751–758. [[CrossRef](#)] [[PubMed](#)]
95. Rayhan, N.; Sano, T.; Qian, Z.R.; Obari, A.K.; Hirokawa, M. Histological and immunohistochemical study of composite neuroendocrine-exocrine carcinomas of the stomach. *J. Med. Investig.* **2005**, *52*, 191–202. [[CrossRef](#)]
96. Cogswell, J.P.; Ward, J.; Taylor, I.A.; Waters, M.; Shi, Y.; Cannon, B.; Kelnar, K.; Kempainen, J.; Brown, D.; Chen, C.; *et al.* Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. *J. Alzheimer's Dis.* **2008**, *14*, 27–41.
97. Wang, W.X.; Huang, Q.; Hu, Y.; Stromberg, A.J.; Nelson, P.T. Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: White matter *versus* gray matter. *Acta Neuropathol.* **2011**, *121*, 193–205. [[CrossRef](#)] [[PubMed](#)]
98. Leidinger, P.; Backes, C.; Deutscher, S.; Schmitt, K.; Mueller, S.C.; Frese, K.; Haas, J.; Ruprecht, K.; Paul, F.; Stahler, C.; *et al.* A blood based 12-miRNA signature of Alzheimer disease patients. *Genome Biol.* **2013**, *14*. [[CrossRef](#)] [[PubMed](#)]

99. Tan, L.; Yu, J.T.; Tan, M.S.; Liu, Q.Y.; Wang, H.F.; Zhang, W.; Jiang, T.; Tan, L. Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. *J. Alzheimer's Dis.* **2014**, *40*, 1017–1027.
100. Bekris, L.M.; Lutz, F.; Montine, T.J.; Yu, C.E.; Tsuang, D.; Peskind, E.R.; Leverenz, J.B. MicroRNA in Alzheimer's disease: An exploratory study in brain, cerebrospinal fluid and plasma. *Biomarkers* **2013**, *18*, 455–466. [[CrossRef](#)] [[PubMed](#)]
101. Galimberti, D.; Villa, C.; Fenoglio, C.; Serpente, M.; Ghezzi, L.; Cioffi, S.M.; Arighi, A.; Fumagalli, G.; Scarpini, E. Circulating mirnas as potential biomarkers in Alzheimer's disease. *J. Alzheimer's Dis.* **2014**, *42*, 1261–1267. [[CrossRef](#)]
102. Gallo, A.; Tandon, M.; Alevizos, I.; Illei, G.G. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. *PLoS ONE* **2012**, *7*, e30679. [[CrossRef](#)] [[PubMed](#)]
103. Cheng, L.; Doecke, J.D.; Sharples, R.A.; Villemagne, V.L.; Fowler, C.J.; Rembach, A.; Martins, R.N.; Rowe, C.C.; Macaulay, S.L.; Masters, C.L.; *et al.* Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. *Mol. Psychiatry* **2014**, *20*, 1188–1196. [[CrossRef](#)] [[PubMed](#)]
104. Margis, R.; Margis, R.; Rieder, C.R. Identification of blood micrnas associated to Parkinsonis disease. *J. Biotechnol.* **2011**, *152*, 96–101. [[CrossRef](#)] [[PubMed](#)]
105. Martins, M.; Rosa, A.; Guedes, L.C.; Fonseca, B.V.; Gotovac, K.; Violante, S.; Mestre, T.; Coelho, M.; Rosa, M.M.; Martin, E.R.; *et al.* Convergence of mirna expression profiling, α -synuclein interacton and GWAS in Parkinson's disease. *PLoS ONE* **2011**, *6*, e25443. [[CrossRef](#)] [[PubMed](#)]
106. Cardo, L.F.; Coto, E.; de Mena, L.; Ribacoba, R.; Moris, G.; Menendez, M.; Alvarez, V. Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. *J. Neurol.* **2013**, *260*, 1420–1422. [[CrossRef](#)] [[PubMed](#)]
107. Soreq, L.; Bergman, H.; Israel, Z.; Soreq, H. Overlapping molecular signatures in Parkinson's patients' leukocytes before and after treatment and in mouse model brain regions. *CNS Neurol. Disord. Drug Targets* **2013**, *12*, 1086–1093. [[CrossRef](#)] [[PubMed](#)]
108. Minones-Moyano, E.; Porta, S.; Escaramis, G.; Rabionet, R.; Iraola, S.; Kagerbauer, B.; Espinosa-Parrilla, Y.; Ferrer, I.; Estivill, X.; Marti, E. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. *Hum. Mol. Genet.* **2011**, *20*, 3067–3078. [[CrossRef](#)] [[PubMed](#)]
109. Vella, L.J.; Sharples, R.A.; Lawson, V.A.; Masters, C.L.; Cappai, R.; Hill, A.F. Packaging of prions into exosomes is associated with a novel pathway of PrP processing. *J. Pathol.* **2007**, *211*, 582–590. [[CrossRef](#)] [[PubMed](#)]
110. Fevrier, B.; Vilette, D.; Archer, F.; Loew, D.; Faigle, W.; Vidal, M.; Laude, H.; Raposo, G. Cells release prions in association with exosomes. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 9683–9688. [[CrossRef](#)] [[PubMed](#)]
111. Eisele, Y.S.; Obermuller, U.; Heilbronner, G.; Baumann, F.; Kaeser, S.A.; Wolburg, H.; Walker, L.C.; Staufenbiel, M.; Heikenwalder, M.; Jucker, M. Peripherally applied A β -containing inoculates induce cerebral β -amyloidosis. *Science* **2010**, *330*, 980–982. [[CrossRef](#)] [[PubMed](#)]
112. Hamaguchi, T.; Eisele, Y.S.; Varvel, N.H.; Lamb, B.T.; Walker, L.C.; Jucker, M. The presence of A β seeds, and not age per se, is critical to the initiation of A β deposition in the brain. *Acta Neuropathol.* **2012**, *123*, 31–37. [[CrossRef](#)] [[PubMed](#)]
113. Nath, S.; Agholme, L.; Kurudenkandy, F.R.; Granseth, B.; Marcusson, J.; Hallbeck, M. Spreading of neurodegenerative pathology via neuron-to-neuron transmission of β -amyloid. *J. Neurosci.* **2012**, *32*, 8767–8777. [[CrossRef](#)] [[PubMed](#)]
114. Domert, J.; Rao, S.B.; Agholme, L.; Brorsson, A.C.; Marcusson, J.; Hallbeck, M.; Nath, S. Spreading of amyloid- β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. *Neurobiol. Dis.* **2014**, *65*, 82–92. [[CrossRef](#)] [[PubMed](#)]
115. Joshi, P.; Turola, E.; Ruiz, A.; Bergami, A.; Libera, D.D.; Benussi, L.; Giussani, P.; Magnani, G.; Comi, G.; Legname, G.; *et al.* Microglia convert aggregated amyloid- β into neurotoxic forms through the shedding of microvesicles. *Cell Death Differ.* **2014**, *21*, 582–593. [[CrossRef](#)] [[PubMed](#)]
116. Martins, I.C.; Kuperstein, I.; Wilkinson, H.; Maes, E.; Vanbrabant, M.; Jonckheere, W.; van Gelder, P.; Hartmann, D.; D'Hooge, R.; de Strooper, B.; *et al.* Lipids revert inert A β amyloid fibrils to neurotoxic protofibrils that affect learning in mice. *EMBO J.* **2008**, *27*, 224–233. [[CrossRef](#)] [[PubMed](#)]

117. Guo, J.L.; Lee, V.M. Seeding of normal tau by pathological tau conformers drives pathogenesis of alzheimer-like tangles. *J. Biol. Chem.* **2011**, *286*, 15317–15331. [[CrossRef](#)] [[PubMed](#)]
118. Clavaguera, F.; Bolmont, T.; Crowther, R.A.; Abramowski, D.; Frank, S.; Probst, A.; Fraser, G.; Stalder, A.K.; Beibel, M.; Staufenbiel, M.; *et al.* Transmission and spreading of tauopathy in transgenic mouse brain. *Nat. Cell. Biol.* **2009**, *11*, 909–913. [[CrossRef](#)] [[PubMed](#)]
119. Liu, L.; Drouet, V.; Wu, J.W.; Witter, M.P.; Small, S.A.; Clelland, C.; Duff, K. Trans-synaptic spread of tau pathology *in vivo*. *PLoS ONE* **2012**, *7*, e31302. [[CrossRef](#)] [[PubMed](#)]
120. Luk, K.C.; Song, C.; O'Brien, P.; Stieber, A.; Branch, J.R.; Brunden, K.R.; Trojanowski, J.Q.; Lee, V.M. Exogenous α -synuclein fibrils seed the formation of lewy body-like intracellular inclusions in cultured cells. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 20051–20056. [[CrossRef](#)] [[PubMed](#)]
121. Luk, K.C.; Kehm, V.; Carroll, J.; Zhang, B.; O'Brien, P.; Trojanowski, J.Q.; Lee, V.M. Pathological α -synuclein transmission initiates parkinson-like neurodegeneration in nontransgenic mice. *Science* **2012**, *338*, 949–953. [[CrossRef](#)] [[PubMed](#)]
122. McLean, P.J.; Kawamata, H.; Ribich, S.; Hyman, B.T. Membrane association and protein conformation of α -synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. *J. Biol. Chem.* **2000**, *275*, 8812–8816. [[CrossRef](#)] [[PubMed](#)]
123. Davidson, W.S.; Jonas, A.; Clayton, D.F.; George, J.M. Stabilization of α -synuclein secondary structure upon binding to synthetic membranes. *J. Biol. Chem.* **1998**, *273*, 9443–9449. [[CrossRef](#)] [[PubMed](#)]
124. Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **1998**, *391*, 806–811. [[CrossRef](#)] [[PubMed](#)]
125. Tavernarakis, N.; Wang, S.L.; Dorovkov, M.; Ryazanov, A.; Driscoll, M. Heritable and inducible genetic interference by double-stranded RNA encoded by transgenes. *Nat. Genet.* **2000**, *24*, 180–183. [[CrossRef](#)] [[PubMed](#)]
126. Cooper, J.M.; Wiklander, P.B.; Nordin, J.Z.; Al-Shawi, R.; Wood, M.J.; Vithlani, M.; Schapira, A.H.; Simons, J.P.; El-Andaloussi, S.; Alvarez-Erviti, L. Systemic exosomal siRNA delivery reduced α -synuclein aggregates in brains of transgenic mice. *Mov. Disord.* **2014**, *29*, 1476–1485. [[CrossRef](#)] [[PubMed](#)]
127. Haney, M.J.; Klyachko, N.L.; Zhao, Y.; Gupta, R.; Plotnikova, E.G.; He, Z.; Patel, T.; Piroyan, A.; Sokolsky, M.; Kabanov, A.V.; *et al.* Exosomes as drug delivery vehicles for Parkinson's disease therapy. *J. Control. Release* **2015**, *207*, 18–30. [[CrossRef](#)] [[PubMed](#)]
128. Ciardiello, C.; Cavallini, L.; Spinelli, C.; Yang, J.; Reis-Sobreiro, M.; de Candia, P.; Minciacchi, V.R.; di Vizio, D. Focus on extracellular vesicles: New frontiers of cell-to-cell communication in cancer. *Int. J. Mol. Sci.* **2016**, *17*. [[CrossRef](#)] [[PubMed](#)]
129. Iraci, N.; Leonardi, T.; Gessler, F.; Vega, B.; Pluchino, S. Focus on extracellular vesicles: Physiological role and signaling properties of extracellular membrane vesicles. *Int. J. Mol. Sci.* **2016**, *17*. [[CrossRef](#)] [[PubMed](#)]
130. Ohno, S.I.; Drummen, G.P.C.; Kuroda, M. Focus on extracellular vesicles: Development of exosome-based therapeutic systems. *Int. J. Mol. Sci.* **2016**, *17*. [[CrossRef](#)] [[PubMed](#)]
131. Zhang, B.; Tan, K.H.; Lim, S.K. Focus on extracellular vesicles: Therapeutic efficacy of stem cell-derived extracellular vesicles. *Int. J. Mol. Sci.* **2016**, *17*. [[CrossRef](#)] [[PubMed](#)]

